Skip to main content

Table 4 Patient-Reported Outcomes Related to Worry

From: Patient-reported outcomes associated with cancer screening: a systematic review

 

Study Design

Screening

Measure†

Result

Screening

2 mo

3 mo

4 mo

5 mo

6 mo

7 mo–11 mo

12 mo

Baseline

Within 1 mo

Mean (SD)

Mean (SD)

Mean (SD)

Brain et al 2016 [37]

N = 1579–2019

N = 73 (−)

N = 41 (Incidental)

N = 788 (+)/Repeat N = 48 (+)/MDT

RCT

LDCT

CWS

Total (+/−/Incidental)

8.8

8.5 (8.4–8.6)

       

(−)

8.3 (8.2–8.5)

       

Incidental

8.6 (8.0–9.2)

       

(+)/Repeat scan

9.3 (9.2–9.5)*

       

(+)/MDT referral

11.9 (11.1–12.7)*

       

Control

8.7

8.3 (8.2–8.4)

       

Ong et al 2016 [50]

N = 234–327

Prospective questionnaire

DARE

Cancer worry

Total (regardless of result)

NA

• Worried about dying soon: 4%

• Thought about anal cancer a lot: 3%

• Worried about developing anal cancer: 3%

     

Landstra et al 2013 [51]

N = 50–271

• HIV+ and MSM with history of (non-cancer) anal disease

Prospective longitudinal survey

Anal Swab + HRA

ASQ

(+)

≈1.3a

≈1.8a

≈1.7a

     

(−)

≈1.2a

≈1.2a

≈0.9a

     

FP

≈1.3a

≈1.8a

≈1.2a

     

Ruberg et al 2016 [47]

N = 180 (Total)

N = 16 (Abnormal)

• Age: 30–60 years

• Women living in Netherlands

Prospective longitudinal

TVS/CA125

MWM

Total (Abnormal, Normal)

3.8 (1.7)

3.3 (1.6)

2.6 (1.5)

     

Abnormal

4.5 (1.8)

3.8 (1.7)

3.5 (1.8)

     

Normal

3.7 (1.7)

3.2 (1.6)

2.5 (1.4)*

     

CWS

Total (Abnormal, Normal)

2.1 (1.6)

1.7 (1.3)

1.3 (1.2)

     

Abnormal

2.7 (2.0)

1.9 (1.0)

2.0 (1.2)

     

Normal

2.1 (1.6)

1.7 (1.3)

1.3 (1.2)*

     

Byrne et al 2008 [44]

N = 341

• Age: 50–79 years

Prospective cohort

LDCT

PCQ

Suspicious

6.4 (2.3)

8.5 (2.6)*

   

7.4 (3.0)

 

7.1 (2.5)

Indeterminate

7.2 (2.8)

7.5 (2.7)

   

7.1 (2.6)

 

7.1 (2.7)

(−)

7.0 (2.5)

7.0 (2.4)

   

6.5 (2.4)

 

6.7 (2.3)

Tyndel 2007 [52]

Recall: 112

Clear: 1174

• Age: 35–49 years

• Women with a moderate or high risk of familial breast cancer

Prospective cohort

MMG

CWS

Recall

11.6 (2.9)

11.7 (2.9)

   

10.4 (2.7)*

  

All-clear

11.0 (2.9)

10.6 (2.6)*

   

10.1 (2.5)*

  
  1. *Indicating statistical significance, p < 0.05
  2. †CWS, MWM, PCQ: higher scores indicate greater worry
  3. aEstimated numbers from figure in manuscript
  4. Abbreviations: ASQ anal screening questionnaire, CA-125 ovarian tumor marker, CWS cancer worry scale, DARE digital anal rectal examination, FP false positive, HRA high resolution anoscopy, LDCT low-dose computed tomography, MDT multidisciplinary team, MMG mammogram, MSM men who have sex with men, MWM Magnitude Worry Measure, NA not applicable, PCQ Psychological Consequences Questionnaire, RCT randomized controlled trial, SD standard deviation, TVS transvaginal ultrasound scan
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us